Schwab Charles Investment Management Inc. increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 335,899 shares of the biotechnology company’s stock after buying an additional 15,414 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in BioMarin Pharmaceutical were worth $29,953,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Creative Planning grew its holdings in shares of BioMarin Pharmaceutical by 52.4% during the fourth quarter. Creative Planning now owns 6,192 shares of the biotechnology company’s stock valued at $552,000 after buying an additional 2,129 shares during the last quarter. Gateway Investment Advisers LLC purchased a new stake in shares of BioMarin Pharmaceutical during the fourth quarter valued at $863,000. National Pension Service grew its holdings in shares of BioMarin Pharmaceutical by 5.8% during the fourth quarter. National Pension Service now owns 178,095 shares of the biotechnology company’s stock valued at $15,881,000 after buying an additional 9,772 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of BioMarin Pharmaceutical by 6.6% during the fourth quarter. Bank of Montreal Can now owns 109,134 shares of the biotechnology company’s stock valued at $9,732,000 after buying an additional 6,802 shares during the last quarter. Finally, Atlantic Trust Group LLC purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $1,997,000. 98.81% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ BMRN) opened at $83.28 on Tuesday. BioMarin Pharmaceutical Inc. has a 1-year low of $78.50 and a 1-year high of $100.51. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81.

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,200 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $85.64, for a total value of $102,768.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director V Bryan Lawlis sold 3,750 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $88.84, for a total transaction of $333,150.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,750 shares of company stock worth $8,159,588. 1.85% of the stock is owned by corporate insiders.

A number of equities research analysts have recently weighed in on BMRN shares. Stifel Nicolaus dropped their price objective on shares of BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, October 27th. BMO Capital Markets reissued a “buy” rating and set a $117.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, October 20th. SunTrust Banks set a $115.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $130.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Sunday, October 29th. Finally, Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $101.00 price objective on the stock in a report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $111.60.

ILLEGAL ACTIVITY WARNING: “BioMarin Pharmaceutical Inc. (BMRN) Stake Boosted by Schwab Charles Investment Management Inc.” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2018/02/13/biomarin-pharmaceutical-inc-bmrn-stake-boosted-by-schwab-charles-investment-management-inc.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.